Form 4: Celldex Therapeutics Director Granted Stock Options

Celldex Therapeutics, Inc. reports the grant of non-qualified stock options to Director Garry Arthur Neil.

Summary

• Director Garry Arthur Neil was granted 26,000 non-qualified stock options by Celldex Therapeutics, Inc.
• The options have an exercise price of $34.09 and are exercisable starting June 25, 2027, with an expiration date of June 25, 2036.
• This grant was made under the company's 2021 Omnibus Equity Incentive Plan.
• The earliest transaction date reported is June 25, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation practice (stock option grant) rather than a significant financial event or strategic shift.

Positives

• Grant of stock options to a director can align management incentives with shareholder value.
• The long expiration date of the options (2036) suggests a long-term commitment and outlook for the company's performance.

Risks

• The value of the stock options is subject to market fluctuations and the company's future stock price performance.
• If the stock price does not exceed the exercise price of $34.09, the options may not be exercised profitably.

Future Outlook

The grant of stock options with a long-term expiration date suggests management's confidence in the future performance and stock appreciation of Celldex Therapeutics.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain key talent and align their interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also signals management's long-term commitment and potential for stock appreciation.
• Employees: The existence of an equity incentive plan can positively impact employee morale and retention.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Director Grant, Equity Incentive Plan, Beneficial Ownership, SEC Filing